ROIV
Roivant Sciences Ltd.
$40.82
-0.12
(-0.29%)
Mkt Cap
29.49B
Volume
5,963,669
52W Range
13.81-42.5
Sector
Healthcare
Beta
1.12
EPS (TTM)
-0.38 USD
P/E Ratio
-64.42
Revenue (TTM)
7.53M USD
Rev Growth (5Y)
-19.1%
EPS Growth (5Y)
N/A
Company Description
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M | 23.80M | 67.69M |
| Net Income | (299.77M) | (171.98M) | 4.35B | (1.01B) | (845.26M) | (809.23M) | 1.20B |
| EPS | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.18 | 1.75 |
| Free Cash Flow | (758.56M) | (844.05M) | (766.65M) | (856.08M) | (695.16M) | (557.94M) | (766.75M) |
| FCF / Share | -1.09 | -1.16 | -0.98 | -1.20 | -1.04 | -0.81 | -1.12 |
| Operating CF | (750.35M) | (839.45M) | (765.27M) | (843.39M) | (677.73M) | (552.14M) | (761.83M) |
| Total Assets | 5.73B | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B | 2.48B |
| Total Debt | 107.44M | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M | 180.88M |
| Cash & Equiv | 1.42B | 2.72B | 6.54B | 1.68B | 2.06B | 2.13B | 2.19B |
| Book Value | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B | 1.90B | 2.03B |
| Return on Equity | -0.07 | -0.04 | 0.73 | -0.87 | -0.51 | -0.43 | 0.59 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.44M | 2.52M | 2.00M | 1.57M | 2.17M | 7.57M | 9.02M | 4.47M | 7.99M | 28.93M | 15.56M | 3.65M |
| Net Income | (189.83M) | 302.99M | (265.89M) | (113.52M) | (223.35M) | (206.47M) | 169.38M | (230.18M) | 95.30M | (151.12M) | 5.10B | (304.33M) |
| EPS | -0.26 | 0.43 | -0.38 | -0.17 | -0.33 | -0.29 | 0.23 | -0.31 | 0.13 | -0.19 | 6.37 | -0.40 |
| Free Cash Flow | (263.81M) | (165.08M) | (191.55M) | (193.51M) | (208.42M) | (173.38M) | (209.08M) | (267.80M) | (193.79M) | (108.81M) | (210.81M) | (196.70M) |
| FCF / Share | -0.37 | -0.24 | -0.27 | -0.28 | -0.31 | -0.25 | -0.29 | -0.36 | -0.26 | -0.14 | -0.26 | -0.26 |
| Operating CF | (263.39M) | (163.82M) | (196.48M) | (185.66M) | (204.38M) | (172.56M) | (207.25M) | (266.81M) | (192.83M) | (108.46M) | (210.45M) | (196.43M) |
| Total Assets | 5.31B | 5.73B | 5.23B | 5.06B | 5.03B | 5.44B | 5.79B | 6.21B | 6.50B | 7.22B | 7.31B | 2.07B |
| Total Debt | 107.15M | 107.44M | 207.44M | 98.85M | 99.69M | 100.17M | 100.31M | 52.71M | 379.06M | 499.75M | 506.58M | 497.98M |
| Cash & Equiv | 1.25B | 1.42B | 1.48B | 1.24B | 1.24B | 2.72B | 1.99B | 1.96B | 5.68B | 6.54B | 6.67B | 1.41B |
| Book Value | 4.23B | 4.53B | 4.27B | 4.36B | 4.35B | 4.69B | 5.19B | 5.15B | 5.44B | 5.97B | 6.09B | 948.53M |
| Return on Equity | -0.04 | 0.07 | -0.06 | -0.03 | -0.05 | -0.04 | 0.03 | -0.04 | 0.02 | -0.03 | 0.84 | -0.32 |
ROIV News
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
Stock Futures Mixed to Start Holiday-Shortened Week
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Roivant's experimental lung disease drug meets goals in mid-stage study
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026